AstraZeneca should still know before the end of the year whether its experimental vaccine protects people against Covid-19, Reuters reported, quoting the drugmaker’s chief executive Pascal Soriot.
Soriot said during an online event that AstraZeneca did not yet know the diagnosis, adding that it was not clear if the volunteer had transverse myelitis and more tests were needed.
He said the diagnosis would be submitted to an independent safety committee and this would usually then tell the company whether trials can be resumed.
